IDYA
Price
$26.32
Change
+$0.27 (+1.04%)
Updated
Dec 17, 04:59 PM (EDT)
104 days until earnings call
NUVL
Price
$87.30
Change
-$0.80 (-0.91%)
Updated
Dec 18, 10:41 AM (EDT)
104 days until earnings call
Ad is loading...

IDYA vs NUVL

Header iconIDYA vs NUVL Comparison
Open Charts IDYA vs NUVLBanner chart's image
IDEAYA Biosciences
Price$26.32
Change+$0.27 (+1.04%)
Volume$7.76K
CapitalizationN/A
Nuvalent
Price$87.30
Change-$0.80 (-0.91%)
Volume$100
CapitalizationN/A
IDYA vs NUVL Comparison Chart
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. NUVL commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and NUVL is a StrongBuy.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (IDYA: $26.33 vs. NUVL: $88.10)
Brand notoriety: IDYA and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 104% vs. NUVL: 117%
Market capitalization -- IDYA: $2.28B vs. NUVL: $6.26B
IDYA [@Biotechnology] is valued at $2.28B. NUVL’s [@Biotechnology] market capitalization is $6.26B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than NUVL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while NUVL’s TA Score has 4 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 4 bearish.
  • NUVL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both IDYA and NUVL are a good buy in the short-term.

Price Growth

IDYA (@Biotechnology) experienced а -5.19% price change this week, while NUVL (@Biotechnology) price change was -5.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.45%, and the average quarterly price growth was +4.23%.

Reported Earning Dates

IDYA is expected to report earnings on Apr 01, 2025.

NUVL is expected to report earnings on Apr 01, 2025.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($6.26B) has a higher market cap than IDYA($2.28B). NUVL YTD gains are higher at: 19.717 vs. IDYA (-25.998). IDYA has higher annual earnings (EBITDA): -220.54M vs. NUVL (-240.51M). NUVL has more cash in the bank: 1.17B vs. IDYA (920M). IDYA has higher revenues than NUVL: IDYA (3.92M) vs NUVL (0).
IDYANUVLIDYA / NUVL
Capitalization2.28B6.26B36%
EBITDA-220.54M-240.51M92%
Gain YTD-25.99819.717-132%
P/E RatioN/AN/A-
Revenue3.92M0-
Total Cash920M1.17B79%
Total Debt18.8MN/A-
TECHNICAL ANALYSIS
Technical Analysis
IDYANUVL
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 9 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TYD24.58N/A
N/A
Direxion Daily 7-10 Yr Trs Bull 3X ETF
EQLS21.41-0.02
-0.11%
Simplify Market Neutral Eq Long/Shrt ETF
FDL40.81-0.07
-0.17%
First Trust Morningstar Div Leaders ETF
IQDF24.58-0.08
-0.32%
FlexShares Intl Qual Div ETF
TSLQ21.23-1.70
-7.41%
Tradr 2X Short TSLA Daily ETF

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with GRI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+1.07%
GRI - IDYA
54%
Loosely correlated
+1.88%
PLRX - IDYA
48%
Loosely correlated
+4.74%
PGEN - IDYA
47%
Loosely correlated
+2.46%
INAB - IDYA
47%
Loosely correlated
+2.27%
RCKT - IDYA
46%
Loosely correlated
+1.36%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with ABCZF. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then ABCZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+0.78%
ABCZF - NUVL
51%
Loosely correlated
N/A
NCNA - NUVL
41%
Loosely correlated
+1.19%
ASND - NUVL
40%
Loosely correlated
+2.71%
IDYA - NUVL
39%
Loosely correlated
+1.07%
IMRX - NUVL
38%
Loosely correlated
N/A
More